Objective To investigate the correlation between interleukin-1β(IL-1β),interleukin-1 receptor antagonist(IL-1 ra)and the obesity of polycystic ovary syndrome(PCOS).Methods(1)From Oct.2006 to Jan.2007,118 PCOS patients were enrolled in this study in Peking University Third Hospital,which were divided into 56 patients in obese PCOS group and 62 patients in non-obese PCOS group according to the WHO International Obesity Task Force Asia-Pacific criteria[body mass index(BMI)25 kg/m2].The polymorphism of IL-1β gene promoter region,exon-5 and intron 2 of IL-1 ra gene were detected by PCR.(2)Twenty-nine obese PCOS patients and 31 non-obese PCOS patients were selected randomizedly serum levels of IL-1β,IL-1 ra were measured by ELISA,in the mean time,serum levels of fasting glucose,fasting insulin and the total white blood cell,hypersensitive C-reactive protein levels were measured.Results(1)Genetic test:the frequency of TT genotype and T allele of IL-1β promoter region(-511)in obese PCOS patients were significantly higher than those in non-obese patients(44.6％ vs.11.3％,63.4％ vs.39.5％,all P ＜0.05).The frequency of IL-1 ra Ⅰ / Ⅴ genotype and Ⅴ allele of IL-1 ra gene were 19.6％ and 9.8％ in obese PCOS patients,which were significantly higher than those in non-obese group(3.2％ and 1.6％,P ＜0.05).(2)Serological test:serum level of IL-1β and IL-1ra of(149 ±36)and(284 ±97)ng/L in obese PCOS group which were significantly higher than those in non-obese PCOS group[(96 ± 42)and(208 ± 84)ng/L,P ＜ 0.05].Fasting blood glucose,fasting insulin and hypersensitive C-reactive protein and white blood cell count were(5.1 ± 0.7)mmol/L,(17 ± 9)mU/L,(1.5 ± 0.6)mg/L and(7.0 ± 2.3)× 109/L in obese PCOS group,which were significantly higher than in non-obese PCOS group[(4.9 ±0.5)mmol/L,(11 ±8)mU/L,(0.9 ±0.4)mg/L and(5.9 ±1.3)× 109/L,P＜0.05].(3)The correlation between interleukin and BMI: serum levels of IL-1β(r =0.673)and IL-1 ra(r =0.557)were positively correlated with BMI in PCOS patients(P ＜ 0.05).Conclusions Inflammatory factors IL-1β and IL-1ra had correlation with obesity of PCOS patients,PCOS patients who carried T allele of IL-1β gene promoter region(-511)and Ⅴ allele of IL-1ra gene were high risk of obesity.

Objective To study the effect of clomiphene citrate (CC) and human menopausal gonadotropin (hMG) on the expression of integrins ? 4? 1 during implantation window in endometrium. Methods Endometrium integrin ? 4? 1 expression was detected by immunohistochemistry method in the mid secretory phase of 48 normal natural cycles. CC+hCG or CC+hMG+hCG cycles in 30 polycystic ovary syndrom (PCOS) patients and 48 normal women. Results The expression of endometrial integrin ? 4? 1 was stronger in the natural cycls than those of ovulation induction cycles with CC+hCG or CC+hMG+hCG. So was the pregnancy cycles as compared with the non pregnant cycles. Conclusion The endometrial receptivity in the min luteal phase and pregnant rate declined during ovulation induction by CC+hCG or CC+hMG+hCG in either normal women or PCOS patients.

Objective To investigate the incidence of follicular stimulating hormone receptor (FSHR) gene C566T mutation in Chinese women with premature ovarian failure (POF) and to explore the etiologies of POF. Methods This case-control study was carried out between 73 Chinese women with idiopathic POF (POF group) and 35 controls (control group), including 25 normal females with a regular menstrual history and 10 normal post-menopause women. DNA was extracted from the peripheral blood of patients and controls. The exon 7 of FSHR gene was amplified by PCR. PCR products were subsequently digested by the enzyme BsmI and then subjected to electrophoresis on agarose gels and stained with ethidium bromide to determine the C566T mutation. DNA samples of random sampling were further analysed by sequencing the PCR products to confirm the mutation. Results BsmI digestion resulting in two fragments of 51 and 27 base pairs was noted for all 73 POF patients and 35 controls. PCR sequencing confirmed that the 566 allele of FSHR gene is C, demonstrating normal FSHR allele. Conclusions No FSHR gene C566T mutation is present in POF patients and controls. FSHR C566T mutation may be rare in Chinese women with POF.

Objective: To screen out serum protein profiling of polycystic ovary syndrome(PCOS) by surface - enhancedlaser desorption/ ionization time of flight mass spectrometry (SELDI-TOF MS) for discovering the discriminatory proteins. Methods: Thirty one women with PCOS and thirty healthy women were detected by Weak Cation Exchange(WCX2)chip. ProteinChip reader and Biomarker Wizard software from Ciphergen Inc were combined with a bioinformatics method (support vector machines, SVM ) to analyze protein fingerprinting. Results: There were 4 proteins which were obviously different between the PCOS group and the control. Three of them were up-regulated, and one down-regulated. To set up a analysis model by SVM using the 4 proteins could successfully distinguish between PCOS and the normal control. The corresponding sensitivity, specificity and positive predict value were 86.7%, 83.3%, 87.2%, resectively. Conclusion: Using ProteinChip technology can screen out serum discriminatory proteins quickly and efficiently. Combined with SVM, an optimal fingerprinting model has been set up, which can easily predict PCOS. In disease state of PCOS, there are significant variations which consist of four proteins. To investigate those four discriminatory proteins, especially the protein m/z 6 628 may be of benefit to pathogenic study and the development of biomarkers for PCOS.

ObjectiveTo observe the effect of Shenxiong-Huayu Capsule preconditioning on cell apoptosis and the expression of c-fos、c-jun in the hippocampal CA1 area of rats with acute cerebral ischemia reperfusion injury.Methods SD rats were divided into 3 groups by completely randomized method:sham operation group(n=6),ischemia reperfusion group (model group),and Shenxiong-Huayu Capsule preconditioning group (preconditioning group).The last two groups were divided randomly into 6 h,24 h,48 h and 72 h reperfusion subgroups (each n=6).Intragastric administration for 7 days,once a day.Middle cerebral artery occlusion and reperfushion model was made by an intraluminal filament method.Cell apoptosis was detected by TUNEL method,the expression of c-fos、c-jun was observed by immunohistochemistry.Results ① The number of apoptosic cells at 6、24、48、72hin the hippocampal CA1 area ofrats was respectively (11.17±3.71、39.83 ± 5.67、48.33± 5.32 and 22.17± 3.7 1) single/High power field in the model group,and was respectively (7.83±2.04、15.00±3.58、29.50±6.89 and 10.17±2.32) single/High power field in Shenxiong-Huayu Capsule preconditioning group.Compared with the model group,the number of apoptosic cells at each time point in the hippocampal CA1 area of rats was decreased in Shenxiong-Huayu Capsule preconditioning group(P＜0.05 or P＜0.01 ).② The number ofc-fos at 6、24、48、72 h in the hippocampal CA1 area of rats was respectively (14.50± 3.45、33.67± 1.63、42.33±3.32 and 32.00 ±2.90) single/High power field in the model group,and was respectively (10.17 ± 2.93、21.50 ± 2.43、30.83 ± 3.76 and 25.17 ± 5.27) single/High power field in Shenxiong-Huayu Capsule preconditioning group.The number of c-jun at 6、24、48、72 h in the hippocampal CA1 area of rats was respectively (15.50±4.19、22.83±5.64、33.10±4.19 and 14.67±3.08) single/High power field in the model group,and was respectively (9.67± 3.63、15.67±2.73、21.26±3.63 and 9.33 ±3.61)single/High power field in Shenxiong-Huayu Capsule preconditioning group.Compared with the model group,the expression of c-fos、c-jun at each time point in the hippocampal CA1 area of rats was decreased in Shenxiong-Huayu Capsule preconditioning group (P＜0.05 or P＜0.01).ConclusionShenxiong-Huayu capsule can inhibit apoptosis by restraining the expression of c-fos、c-jun and relive cerebral ischemia reperfusion injury in rats.

Objective To explore the association of the Arg64 polymorphism β-3-adrenergic receptor(β3-AR) gene with polycystic ovary syndrome(PCOS)and its characterization with obesity,insulin resistance(IR)，blood pressure (BP), blood lipid spectrum. Methods The polymorphism of the β-3-AR gene was determined in 163 patients with PCOS and 100 controls. Body mass index(BMI), waist to hip circumference ratio(WHR), BP were examined. Blood glucose,blood lipid spectrum,insulin were also measured. Insulin resistance index was calculated. Results The frequency of Arg64 allele in PCOS women was significantly higher than that of controls(0.33 vs 0.13 respectively, P<0.05). Fasting insulin, insulin resistance index, WHR in Arg64 group were significantly higher than those of Trp64 group. The frequency of Arg64 allele was positively correlated with FINS, insulin resistance index, WHR. Conclusion The Arg64 mutation in the β-3-adrenergic receptor(β-3-AR) gene might contribute to development of PCOS and IR.

OBJECTIVE:To investigate the satisfaction degree of outpatients on policy of separation of clinical pharmacy from 4 third grade hospitals in Shanghai,and provide reference for promoting medical reform policy. METHODS:Parts of outpatients in the 4 new suburb third grade hospitals were investigated by the questionnaire and interview in Shanghai city,and the data was sta-tistically analyzed by Excel software and SPSS 19.0 software. RESULTS:Totally 400 questionnaires were sent out and 368 were valid with effective recovery of 94.3%. The awareness rate of medical separation policy was 81.3% in the outpatients;55.5% of outpatients thought that medicine cost savings effect was not obvious;the overall satisfaction of patients was 91.6%,and the high-est of satisfaction was the service attitude and the lowest was medical expenses. CONCLUSIONS:Policy of separation of clinical pharmacy has reduced the medical expenses,guided the triage treatment of patients partly and improved the satisfaction of patients. It is suggested to shorten the waiting time by optimizing examination process,strengthen price regulation in drug,standardize pro-duction and distribution process,improve use rate of essential medicines and promote clinical rational drug use for further improve-ment of satisfaction.

Objective To introduce the working experience of clinical pharmacists who provide pharmaceutical service in participating integrated diabetes out-patient.Methods Review and analyze the patients' clinical features and the clinical pharmacists' working model and effect in integrated diabetes out-patient of the Sixth People's Hospital Affiliated to Shanghai Jiaotong University.Results Among these patients who got pharmaceutical service in integrated diabetes out-patient, 81.7% were 40 to 70 years old, 51.7% had diabetes for 5 to 10 years, 50.0% were taking oral antidiabetic drugs to control blood glucose, and 90.0% were having complications.After the medication guide by clinical pharmacists,patients' medication compliance was increased from the percentage of 30.0% to 80.0%, the good control rate of blood glucose was increased from the percentage of 8.3% to 41.7%, and the incidence rate of adverse reaction was reduced from 10.0% to 3.3%.Conclusion Clinical pharmacists who actively participate in integrated diabetes out-patient could ensure the effective and safe treatment to diabetic patients.Therefore, this model is worth to be popularized due to professional value of clinical pharmacists.

Objective To evaluate the effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome (PCOS) Methods Rosiglitazone was given 4 mg daily to 30 patients with PCOS for 12 weeks Before and after treatment, body mass index(BMI), plasma glucose, insulin, levels insulin resistance index (HOMA IR), blood lipid spectrum, leptin, neuropeptide Y, and sex hormone concentrations and ovulation rate were determined and compared Results After 12 weeks of treatment, basal insulin level decreased from (18?8) to (12?7) mIU/L ( P

Objective: To measure serum monocyte chemoattractant protein-1 (MCP-1) levels and study its associations with lipoproteins in patients with polycystic ovary syndrome (PCOS). Methods: Sixty-five PCOS women and 20 ovulating normal women with body mass index (BMI)